• Ghorfe1
  • بانک خون بندناف رویان
  • ‌‌پژوهشگاه رویان جهاد دانشگاهی
Archive
Archive
نظر خوانندگان
نظر خوانندگان
Publish date: 91 / 07 / 12 | Rating: Article Rating

In a study funded by the Health Research Board (APO-COLON), we identified the proteasomal subunit Rpt4 to be elevated in colorectal cancer tissue when compared to matched normal tissue. Furthermore, in vitro as well as in vivo xenograft studies using gene silencing approaches suggested that inhibition of Rpt4 function is an attractive new target for the treatment of cancer.

The project aims to further evaluate the future potential of targeting Rpt4 expression as therapies for cancer. Studies include: A) Analysis of Rpt4 expression in tumour samples to examine whether any acute changes can be observed in Rpt4 expression following neoadjuvant radiochemotherapy or during metastatic progression. B) In vitro characterization experiments investigating the specificity of Rpt4 inhibition towards cancer cell survival. C) Identifying small molecule inhibitors of Rpt4, including the development of high-throughput assays.

Person Specification: The candidate should have a PhD in Biochemistry, Pharmacology or Cell Biology, ideally in the field of cancer biology, apoptosis, or proteasomal function. (S)he should have significant research experience in the subject areas described as documented by publications. (S)he needs to be able to independently plan and conduct the research project and to integrate into a interdisciplinary research environment. Grant writing skills and experience in the supervision of undergraduate students in research is of advantage.

Application procedure: Please send a CV and names of at least two referees plus accompanying documentation (such as certificates, publications) to prehn@rcsi.ie.

Closing date: Applications are reviewed on an ongoing basis but should not be received after 31st of October, 2012.

Other information:

http://www.systemsmedicineireland.ie/

Recent publications:

Laussmann MA, Passante E, Hellwig CT, Tomiczek B, Flanagan L, Prehn JH, Huber HJ, Rehm M. Proteasome inhibition can impair caspase-8 activation upon submaximal stimulation of apoptotic tumor necrosis factor-related apoptosis inducing ligand (TRAIL) signaling. J Biol Chem. 2012

Hector S, Rehm M, Schmid J, Kehoe J, McCawley N, Dicker P, Murray F, McNamara D, Kay EW, Concannon CG, Huber HJ, Prehn JH. Clinical application of a systems model of apoptosis execution for the prediction of colorectal cancer therapy responses and personalisation of therapy. Gut. 2012 May;61(5):725-33.

McCawley N, Conlon S, Hector S, Cummins RJ, Dicker P, Johnston PG, Kay EW, McNamara DA, Prehn JH, Concannon CG. Analyzing proteasomal subunit expression reveals Rpt4 as a prognostic marker in stage II colorectal cancer. Int J Cancer. 2012 Aug 15;131(4):E494-500.

Tuffy LP, Concannon CG, D'Orsi B, King MA, Woods I, Huber HJ, Ward MW, Prehn JH. Characterization of Puma-dependent and Puma-independent neuronal cell death pathways following prolonged proteasomal inhibition. Mol Cell Biol. 2010 Dec;30(23):5484-501.

Concannon CG, Koehler BF, Reimertz C, Murphy BM, Bonner C, Thurow N, Ward MW, Villunger A, Strasser A, Kögel D, Prehn JH. Apoptosis induced by proteasome inhibition in cancer cells: predominant role of the p53/PUMA pathway. Oncogene. 2007 Mar 15;26(12):1681-92.

 

Prof Jochen Prehn

prehn@rcsi.ie

Royal College of Surgeons in Ireland, Centre for Systems Medicine

Dublin. Ireland

Ansprechpartner: Prof Jochen Prehn

Related Images
  • Postdoctoral Position in Proteasomal Dysfunction and Cancer Biology -Dublin. Ireland
Post Rating